Aceragen Inc., of Research Triangle Park, N.C., acquired Durham, N.C.-based Enzyvant Inc.’s RVT-801 (now ACG-801), an investigational enzyme replacement therapy for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. Enzyvant will receive an up-front payment and development and sales-based milestones up to $226 million, as well as tiered royalties on net sales. Aceragen entered into a $35 million product financing agreement with Novaquest Capital Management to fund the development program into a potential registrational study.

Biovaxys Technology Corp., of Vancouver, British Columbia, said it signed a definitive exclusive bioproduction agreement with Bioelpida SAS, of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, Biovaxys' vaccine candidate for stage III/stage IV ovarian cancer. Financial terms were not disclosed. Biovaxys expects to be able to prepare its regulatory submission for a phase I study in Europe near the end of this year, with vaccine supply for the planned clinical study available early May 2022.

Cocrystal Pharma Inc., of Bothwell, Wash., disclosed progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2. Cocrystal initiated its COVID-19 program in March 2020 and has since expanded the program with additional development and licensing. In December 2020 Cocrystal selected CDI-45205 as its lead coronavirus development candidate among a group of protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation.

Enteris Biopharma Inc., of Boonton, N.J., disclosed the expansion of its manufacturing facility and the launch of its CDMO business segment. The firm said it now provides bench to market services, including the development, manufacture, testing and release of phase I to phase III trial supplies, as well as commercial production.

Lantern Pharma Inc., of Dallas, said it entered an R&D collaboration with Actuate Therapeutics Inc., of Fort Worth, Texas. The collaboration will focus on leveraging the RADR machine learning technology, large-scale oncology datasets and the AI platform to accelerate key aspects of Actuate's 9-ING-41 drug candidate, a potentially best-in-class GSK-3β inhibitor in active development in multiple phase II trials, including for pancreatic cancer. The collaboration is expected to start immediately and will potentially generate novel intellectual property that will be jointly owned by the companies. Financial terms were not disclosed.

Revive Therapeutics Ltd., of Toronto, said it formed a sponsored research agreement with the University of California, San Francisco to explore its repurposed formulation of bucillamine to treat severe COVID-19. The agreement will support research testing the efficacy of the xanthine oxidase inhibitor in preclinical models of COVID-19 and designing protocols for human trials.

Sonnet Biotherapeutics Holdings Inc., of Princeton, N.J., said it executed a definitive agreement with New Life Therapeutics Pte Ltd. (NLT), of Singapore, for the license of low-dose Interleukin-6 for the treatment of diabetic peripheral neuropathy (DPN). The licensed territory includes the ASEAN countries of Singapore, Malaysia, Indonesia, Thailand, the Philippines, Cambodia, Brunei, Vietnam, Myanmar and Lao PDR. Under the terms, Sonnet is entitled to an up-front payment of $1 million from NLT (including the $500,000 previously paid during 2020). Sonnet is also eligible to receive potential additional amounts up to a maximum of $20 million, in the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 12% to 30% on net sales. NLT will be responsible for conducting a phase Ib/IIa pilot-scale efficacy study with low-dose IL-6 in DPN, to include the ASEAN region, expected to start during the second half of 2021. Sonnet will continue to be the manufacturer of low-dose IL-6 for clinical development and commercial purposes. NLT has an option to negotiate a license for commercial rights in chemotherapy-induced peripheral neuropathy and also has an option to negotiate a license for expanding the exclusive territory to include China and India.

Tryp Therapeutics Inc., of San Diego, said it signed a master service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The collaboration will be initially focused on supporting Tryp's upcoming phase IIa trial for eating disorders.